Inmune Bio, INC 8-K filings

INmune Bio Inc. announced stockholder approval to significantly increase shares under its stock incentive plan and reported positive preclinical results for its XPro drug candidate in an animal model of Alzheimer's disease linked to traumatic brain injury.

INmune Bio Inc. will present at the RBC Capital Markets Global Healthcare Conference on May 20-21, 2025, in New York.

INmune Bio Inc. reported its Q1 2025 financial results, showing a net loss of $9.7 million and provided updates on its clinical programs, including upcoming data releases and regulatory submissions.

INmune Bio dismisses Marcum LLP as its independent auditor due to its acquisition by CBIZ CPAs, and subsequently engages CBIZ CPAs as its new auditor.

INmune Bio Inc. will host a conference call on May 8, 2025, to discuss its first quarter 2025 financial results and provide a corporate update.

INmune Bio Inc. announced a favorable patentability opinion from the United States Patent and Trademark Office for its CORDStrom platform technology.

INmune Bio has partnered with Cell and Gene Therapy Catapult to establish large-scale manufacturing for its cell therapy platforms, initially focusing on CORDStrom for RDEB.

INmune Bio presented a poster detailing patient demographics and biomarker status at enrollment in their MINDFul Phase II trial for early Alzheimers disease.

INmune Bio presented baseline demographics and disease profiles of participants in its MINDFuL Phase II study for early Alzheimer's disease at a major European conference.

INmune Bio Inc. reported its financial results for the year ended December 31, 2024, and provided a business update, including progress on its DN-TNF, CORDStrom, and INKmune platforms.

INmune Bio Inc. will host a conference call on March 27, 2025, to discuss its fourth quarter 2024 financial results and provide a corporate update.

INmune Bio Inc. shared preliminary results from its Phase I/II trial of INKmune in metastatic, castration-resistant prostate cancer (mCRPC) at the Innate Killer Summit in March 2025, highlighting safety and potential immunologic efficacy.

INmune Bio announces the completion of the Phase I portion of its INKmune trial for metastatic castration-resistant prostate cancer and the opening of the Phase II high dose cohort.

INmune Bio plans to submit a Biologics License Application (BLA) to the FDA for CORDStrom, a treatment for recessive dystrophic epidermolysis bullosa (RDEB) in pediatric patients, following positive clinical trial results.

INmune Bio is advancing its pipeline with key milestones expected in 2025, including a BLA submission for CORDStrom in Recessive Dystrophic Epidermolysis Bullosa (RDEB) and top-line results from the Phase 2 trial of XPro in Alzheimer's disease.

INmune Bio has begun the Phase II portion of its clinical trial for INKmune, a novel NK cell therapy, in men with metastatic castration-resistant prostate cancer at the West Los Angeles Veterans Administration Hospital.

INmune Bio has amended its shareholder rights agreement, extending the expiration date to December 30, 2025.

INmune Bio has finalized patient enrollment for its Phase 2 trial targeting early Alzheimer's disease, with 208 participants, exceeding the initial target.

INmune Bio is advancing two novel platforms, XPro for Alzheimer's and INKmune for cancer, with key data readouts expected in the near term.

INmune Bio reports completion of enrollment for its Phase 2 Alzheimer's trial, positive interim analysis of a novel cognitive measure, and third quarter 2024 financial results.

INmune Bio will host a webinar on November 7, 2024, to discuss the use of EMACC for measuring cognitive change in early Alzheimer's trials, following a poster presentation at the CTAD conference.

INmune Bio's research published in Cell Reports shows XPro1595 promotes remyelination in an animal model, suggesting potential for treating demyelinating diseases.

INmune Bio Inc. will host a conference call on October 31, 2024, to discuss its third quarter 2024 financial results and provide a corporate update.

INmune Bio Inc. will participate in the Maxim Healthcare Virtual Summit from October 15-17, 2024, to discuss their clinical-stage inflammation and immunology programs.

INmune Bio reports positive initial safety and efficacy signals from the first cohort of its Phase I/II trial of INKmune in metastatic castration-resistant prostate cancer, showing increased NK cell activity.

INmune Bio announced that additional analysis of its Phase II Alzheimer's trial data demonstrated a strong correlation between its novel cognitive measure, EMACC, and the standard clinical endpoint, CDR-SB.

INmune Bio has successfully raised approximately $13 million through a registered direct offering of common stock and warrants.

INmune Bio Inc. announced its participation in the Baird 2024 Global Healthcare Conference in September and October 2024.

INmune Bio Inc. has entered into an amended agreement to sell up to $75 million of its common stock through an at-the-market offering.

INmune Bio reported its second quarter 2024 financial results and provided a business update, noting progress in its Alzheimer's and cancer clinical trials.